Condition
Temozolomide
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Recruiting2
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05512481Phase 2Recruiting
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
NCT06279767Phase 1Recruiting
Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma
NCT03079440Phase 2Completed
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
NCT03763422Phase 3Terminated
Trial in Low Grade Glioma Patients: Wait or Treat
Showing all 4 trials